智通财经APP讯，正海生物(300653.SZ)发布2025年三季度报告，该公司前三季度营业收入为2.76亿元， 同比减少5.36%。归属于上市公司股东的净利润为6740.22万元，同比减少46.10%。归属于上市公司股东 的扣除非经常性损益的净利润为5918.16万元，同比减少45.34%。基本每股收益为0.37元。 ...

昊海生科公告，第三季度营收为5.95亿元，下降11.29%；净利润为9358.21万元，下降11.39%。前三季 度营收为18.99亿元，下降8.47%；净利润为3.05亿元，下降10.63%。 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2025-006 | 投资者关系活 | □特定对象调研 | □分析师会议 □媒体采访 | | --- | --- | --- | | 动类别 | □业绩说明会 | □新闻发布会 □路演活动 | | | □现场参观 | ■其他（分析师电话会议） | | 参与单位名称 及人员姓名 | 共 49 家机构共计 | 66 名人员参加，详见附件。 | | 时间 | 年 月 日 2025 10 24 | 9:00-9:50 | | 地点 | 电话会议 | | | 上市公司接待 | | 董事长：胡赓熙；总经理：何建明；副总经理/董事会秘书：管祯 | | 人员姓名 | 玮。 一、经营情况介绍 | | | | 经营业绩情况： | | | 投资者关系活 | 2025 年 1-9 | 月，公司实现营业收入 853,360,357.81 元，较上 | | 动主要内容介 | 年 同 期 增 长 | ， 归 属 于 上 市 公 司 股 东 的 净 利 润 为 16.86% | | 绍 | 344,866,533.27 | 元，较上年同期增长 ...

现代的溶瘤病毒疗法，并非简单利用野生病毒，而是基于基因工程技术，对病毒进行精心改造和"武 装"，以使其实现"双重特异性"。 基因改造可以使病毒特异性地在肿瘤细胞内部复制增殖，而对正常细胞秋毫无犯。这通常是利用肿瘤细 胞特有的信号通路来实现，如肿瘤细胞特有的抑癌蛋白信号通路的缺失，让某些病毒得以在其细胞内复 制。此外，改造还会赋予病毒产生"溶瘤"效应的能力，即导致肿瘤细胞裂解死亡，并释放出大量的肿瘤 抗原和新生病毒颗粒，向机体免疫系统"拉响警报"，招募大量免疫细胞前来围剿肿瘤细胞。 "如果病毒没有经过这些改造，不仅会导致身体感染，而且肿瘤细胞杀灭效果差、成本收益比极低。通 过对病毒基因进行优化改造，丰富病毒基因的功能元件，可以在保留其激发免疫反应能力的同时减少其 对身体的危害。"张宏伟说。 业内认为，溶瘤病毒疗法具有多重杀伤机制，不易耐药。与传统靶向药针对单一靶点不同，溶瘤病毒通 过直接裂解和激活免疫双重途径攻击肿瘤细胞。肿瘤细胞很难同时对所有机制产生耐药，这就降低了治 疗失效的风险。 "我们在国际上首创了全新的颅内注射方式，让溶瘤病毒疗法在治疗脑部肿瘤疾病方面更具便利性。"首 都医科大学三博脑科医院副院长张宏 ...

Investment Rating - The report initiates coverage with an "Outperform" rating for Lepu Biopharma-B (2157) [4] Core Views - The company is a leading domestic innovative pharmaceutical enterprise focusing on ADC combined with IO in oncology, with expectations for rapid market penetration following the approval of MRG003 [1][4] - The product pipeline is expected to expand internationally, indicating strong long-term growth potential for the company [1] Financial Summary - Projected total revenue for 2024A, 2025E, 2026E, and 2027E is 368 million, 853 million, 1,204 million, and 1,665 million RMB respectively, reflecting growth rates of 63%, 132%, 41%, and 38% [3] - Gross profit is expected to increase from 292.97 million in 2024A to 1,415.20 million in 2027E, with a gross margin projected to be around 79.66% to 85% [3] - Net profit is forecasted to improve from -411 million in 2024A to -29 million in 2027E, indicating a significant reduction in losses [3] Company Overview - Lepu Biopharma was established in January 2018 and focuses on oncology, particularly targeted and immunotherapy [9] - The company has built a diverse product pipeline through acquisitions and partnerships, including PD-1 antibodies and ADCs [9] - The management team is experienced, with a high concentration of ownership, ensuring stability and strategic direction [13][15] Market Potential - The global and Chinese cancer immunotherapy market is expected to grow significantly, with a CAGR of 16.3% and 25.1% respectively from 2025 to 2030 [28][31] - The PD-1 therapy market in China is projected to reach 582 billion RMB by 2030, with a CAGR of 30.5% from 2020 to 2025 [33][35] ADC Market Growth - The global ADC market is anticipated to reach 66.2 billion USD by 2030, with a CAGR of 30.3% from 2023 to 2030 [41] - The ADC market in China is expected to grow at a CAGR of 72.6% from 2023 to 2028, reaching 38.3 billion RMB [44][45] Product Pipeline and Clinical Development - MRG003 is currently under NDA review and has shown promising results in clinical trials for R/M NPC, with a significant improvement in overall response rates compared to chemotherapy [56][61] - The company is actively exploring combination therapies with PD-1 inhibitors, which may enhance treatment efficacy [60][65]

摘要 ： 此次收购将扩充默克的下游工艺产品组合，助力生物制药疗法（包括单克隆抗体）实现更为高效、更具可线性放大的生产。该交易预计将于2026年第二 季度末完成。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025年10月15日，德国达姆施塔特——全球领先的科技公司默克宣布，其已签署最终协议，收购JSR Life Sciences ( JSR生命科学) 的层 析业务。JSR Life Sciences是CDMO(合同开发和制造组织)、临床前和转化临床研究，以及生物工艺解决方案领域的领导者。借助先进的 Protein A (蛋白A) 层析技术能力，此次收购将扩充默克的下游工艺产品组合，助力生物制药疗法（包括单克隆抗体）实现更为高效、更具可 线性放大的生产。该交易预计将于2026年第二季度末完成。 "此次收购将加强我们在生物工艺市场的地位，并彰显我们对长期投资单克隆抗体生产技术的承诺，" 默克生命科学业务工艺解决方案负责人 Sebas tián Arana表示 。 "我们的产品组合与JSR的Protein A专业知识相结合，可使我们更好地帮 ...

艾德生物公告，第三季度营收为2.86亿元，下降6.12%；净利润为7346.86万元，下降11.92%。前三季度 营收为8.66亿元，增长2.08%；净利润为2.63亿元，增长15.50%。 ...

Group 1 - The company, Jindike, announced that its second board meeting will be held on October 24, 2025, to discuss the cancellation of the supervisory board and amendments to the company’s articles of association [1] - For the year 2024, Jindike's revenue composition is entirely from biopharmaceuticals, accounting for 100.0% [1] - As of the report date, Jindike's market capitalization is 2.1 billion yuan [2] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [2] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [2]

Core Viewpoint - Watson Bio (300142) is actively managing the production, approval, and sales of its bivalent HPV vaccine through its subsidiary Yuxi Zerun Biotechnology Co., Ltd, ensuring product availability and compliance with policy changes [1] Group 1 - The bivalent HPV vaccine's production and sales processes are currently operating normally [1] - The company is monitoring policy adjustments and is prepared to take proactive measures to respond [1] - The goal is to ensure product supply and benefit a wider audience [1]

Core Insights - Suzhou Ribobio Technology Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB announced that the European Medicines Agency (EMA) granted orphan drug designation for their siRNA candidate drug RBD1016, aimed at treating hepatitis D virus (HDV) infection [1][2] Group 1: Orphan Drug Designation - The orphan drug designation by EMA is intended to encourage therapies for rare diseases with a prevalence of less than 5 in 10,000, which pose a serious threat to life or cause chronic debilitating conditions [1] - This designation provides innovative drugs with better regulatory pathways and commercialization incentives, allowing for faster patient access [1] Group 2: Clinical Development - RBD1016 is being developed using Ribobio's proprietary RiboGalSTARTM liver-targeted delivery platform, which has demonstrated safety, efficacy, and long-lasting effects through multiple clinical studies [1] - The drug is currently advancing through Phase II clinical trials for both hepatitis B and D globally [1] Group 3: Company Statements - The co-CEO and Global R&D President of Ribobio stated that the orphan drug designation is a significant milestone for RBD1016, enhancing its development and commercialization prospects [2] - The company is committed to advancing the clinical research of RBD1016 to provide new treatment options for patients suffering from this rare disease [2]